TABLE V.

Association of MBL2 genotypes on CNS progression-free survival in children: Age (≥2 vs <2 y)

MBL2 genotypes compared	Age ≥2 y: RH (95% CI), P value	Age <2 y: RH (95% CI), P value
O/O vs A/O*	1.93 (0.41-9.01), .40	2.78 (1.07-7.21), .035
Adjusted†	4.72 (0.43-52.1), .20	3.56 (1.24-10.3), .019
Adjusted‡	3.71 (0.67-20.4),.13	3.08 (1.11-8.54), .031
Adjusted§	2.25 (0.44-11.6), .33	3.11 (1.14-8.47), .027
O/O vs A/A*	1.33 (0.63-2.81), .45	1.69 (1.06-2.69), .027
Adjusted†	1.00 (0.35-2.86), 1.00	1.75 (1.06-2.90), .028
Adjusted‡	1.46 (0.68-3.13), .33	1.65 (1.01-2.69), .045
Adjusted§	1.85 (0.82-4.15), .14	1.67 (1.02-2.73), .042
O/O vs A/O+A/A*	1.78 (0.42-7.62), .44	2.82 (1.14-7.00), .03
Adjusted†	1.30 (0.17-10.28), .80	3.38 (1.31-8.74), .012
Adjusted‡	2.25 (0.50-10.1), .29	2.81 (1.10-7.16), .031
Adjusted§	2.64 (0.58-12.0), .21	3.05 (1.19-7.77), .020

^*Unadjusted.

^†Adjusted for CD4⁺ lymphocyte count, HIV-1 RNA, treatments, race, and sex.

^‡Adjusted for CCR5-wt/Δ32, -59029-G/A, CX₃CR1-249-V/I, -280-T/M, and SDF-1-180-G/A.

^§Adjusted for MBL2-H/L, MBL2-P/Q, and MBL2-X/Y.